<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of constriction of coronary blood vessels or of those of the extremities (ergotism), or of rapid elevation of blood pressure.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPEVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye by decrease of its hepatic metabolism by the therapy with the two medications. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)" code="R01AA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS" code="N02CC-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of coronary arteries

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 6 to 24 hours, depending on the triptan, between its dose and that of the ergot alkaloid.</COMMENT>
</INTERACTION>
</INTERACTIONS>
